KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Historic Capital Leases for Aquestive Therapeutics (AQST) over the last 3 years, with Q3 2025 value amounting to $122000.0.

  • Aquestive Therapeutics' Capital Leases fell 2026.14% to $122000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $122000.0, marking a year-over-year decrease of 2026.14%. This contributed to the annual value of $146000.0 for FY2024, which is 1560.69% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Capital Leases is $122000.0, which was down 2026.14% from $130000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' Capital Leases' 5-year high stood at $173000.0 during Q4 2023, with a 5-year trough of $122000.0 in Q3 2025.
  • Moreover, its 3-year median value for Capital Leases was $149500.0 (2024), whereas its average is $148625.0.
  • Its Capital Leases has fluctuated over the past 5 years, first plummeted by 1560.69% in 2024, then plummeted by 2026.14% in 2025.
  • Over the past 3 years, Aquestive Therapeutics' Capital Leases (Quarter) stood at $173000.0 in 2023, then dropped by 15.61% to $146000.0 in 2024, then decreased by 16.44% to $122000.0 in 2025.
  • Its last three reported values are $122000.0 in Q3 2025, $130000.0 for Q2 2025, and $138000.0 during Q1 2025.